Logo image of ECAT

BLACKROCK ESG CAP ALL TRM TR (ECAT) Stock Overview

NYSE:ECAT - US09262F1003

16.605 USD
+0.3 (+1.87%)
Last: 8/22/2025, 12:12:23 PM
Fundamental Rating

3

Taking everything into account, ECAT scores 3 out of 10 in our fundamental rating. ECAT was compared to 0 industry peers in the Unkown industry. ECAT has a bad profitability rating. Also its financial health evaluation is rather negative. ECAT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ECAT had positive earnings in the past year.
ECAT had a positive operating cash flow in the past year.
ECAT Yearly Net Income VS EBIT VS OCF VS FCFECAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -500M -1B -1.5B -2B

1.2 Ratios

The 3 year average ROIC (1.31%) for ECAT is below the current ROIC(1.57%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.71%
ROE 13.81%
ROIC 1.57%
ROA(3y)4.06%
ROA(5y)N/A
ROE(3y)3.82%
ROE(5y)N/A
ROIC(3y)1.31%
ROIC(5y)N/A
ECAT Yearly ROA, ROE, ROICECAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 10 -10

1.3 Margins

In the last couple of years the Profit Margin of ECAT has declined.
Industry RankSector Rank
OM 56.45%
PM (TTM) 388.71%
GM 61.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-48.47%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ECAT Yearly Profit, Operating, Gross MarginsECAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 1K 2K

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, ECAT has less shares outstanding
Compared to 1 year ago, ECAT has an improved debt to assets ratio.
ECAT Yearly Shares OutstandingECAT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M 80M 100M
ECAT Yearly Total Debt VS Total AssetsECAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

ECAT has an Altman-Z score of 6.51. This indicates that ECAT is financially healthy and has little risk of bankruptcy at the moment.
The Debt to FCF ratio of ECAT is 0.01, which is an excellent value as it means it would take ECAT, only 0.01 years of fcf income to pay off all of its debts.
A Debt/Equity ratio of 0.00 indicates that ECAT is not too dependend on debt financing.
Although ECAT does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Altman-Z 6.51
ROIC/WACCN/A
WACCN/A
ECAT Yearly LT Debt VS Equity VS FCFECAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 1B -1B 2B -2B

2.3 Liquidity

A Current Ratio of 0.01 indicates that ECAT may have some problems paying its short term obligations.
A Quick Ratio of 0.01 indicates that ECAT may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.01
Quick Ratio 0.01
ECAT Yearly Current Assets VS Current LiabilitesECAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

ECAT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.89%.
ECAT shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 45.23% yearly.
ECAT shows a small growth in Revenue. In the last year, the Revenue has grown by 4.50%.
Measured over the past years, ECAT shows a very strong growth in Revenue. The Revenue has been growing by 175.73% on average per year.
EPS 1Y (TTM)-14.89%
EPS 3Y45.23%
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)4.5%
Revenue growth 3Y175.73%
Revenue growth 5YN/A
Sales Q2Q%-0.47%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ECAT Yearly Revenue VS EstimatesECAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 20M 40M 60M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 6.92 indicates a rather cheap valuation of ECAT.
Compared to an average S&P500 Price/Earnings ratio of 26.76, ECAT is valued rather cheaply.
Industry RankSector Rank
PE 6.92
Fwd PE N/A
ECAT Price Earnings VS Forward Price EarningsECAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 4.88
EV/EBITDA N/A
ECAT Per share dataECAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 21.84%, ECAT is a good candidate for dividend investing.
Compared to an average S&P500 Dividend Yield of 2.36, ECAT pays a better dividend.
Industry RankSector Rank
Dividend Yield 21.84%

5.2 History

ECAT has been paying a dividend for over 5 years, so it has already some track record.
ECAT has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years3
Div Non Decr Years3
ECAT Yearly Dividends per shareECAT Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

119.50% of the earnings are spent on dividend by ECAT. This is not a sustainable payout ratio.
DP119.5%
EPS Next 2YN/A
EPS Next 3YN/A
ECAT Yearly Income VS Free CF VS DividendECAT Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2021 2022 2023 2024 0 -500M -1B -1.5B -2B
ECAT Dividend Payout.ECAT Dividend Payout, showing the Payout Ratio.ECAT Dividend Payout.PayoutRetained Earnings

More info and screens

BLACKROCK ESG CAP ALL TRM TR

NYSE:ECAT (8/22/2025, 12:12:23 PM)

16.605

+0.3 (+1.87%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)09-01 2025-09-01
Inst Owners44.94%
Inst Owner Change0.68%
Ins Owners0.11%
Ins Owner Change86.97%
Market Cap1.65B
Analysts0
Price TargetN/A
Short Float %0.15%
Short Ratio0.44
Dividend
Industry RankSector Rank
Dividend Yield 21.84%
Yearly Dividend2.87
Dividend Growth(5Y)N/A
DP119.5%
Div Incr Years3
Div Non Decr Years3
Ex-Date08-15 2025-08-15 (0.29017)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 6.92
Fwd PE N/A
P/S 26.61
P/FCF 4.88
P/OCF 4.88
P/B 0.95
P/tB 0.95
EV/EBITDA N/A
EPS(TTM)2.4
EY14.45%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)3.4
FCFY20.49%
OCF(TTM)3.4
OCFY20.49%
SpS0.62
BVpS17.55
TBVpS17.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.71%
ROE 13.81%
ROCE 2%
ROIC 1.57%
ROICexc 1.57%
ROICexgc 1.57%
OM 56.45%
PM (TTM) 388.71%
GM 61.29%
FCFM 545.16%
ROA(3y)4.06%
ROA(5y)N/A
ROE(3y)3.82%
ROE(5y)N/A
ROIC(3y)1.31%
ROIC(5y)N/A
ROICexc(3y)1.31%
ROICexc(5y)N/A
ROICexgc(3y)1.34%
ROICexgc(5y)N/A
ROCE(3y)1.67%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-48.47%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality 140.25%
Current Ratio 0.01
Quick Ratio 0.01
Altman-Z 6.51
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.89%
EPS 3Y45.23%
EPS 5YN/A
EPS Q2Q%-25%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.5%
Revenue growth 3Y175.73%
Revenue growth 5YN/A
Sales Q2Q%-0.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y103.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y103.61%
OCF growth 3YN/A
OCF growth 5YN/A